Hypogonadism, Male clinical trials at University of California Health

2 research studies open to eligible people

Showing trials for

  • 52 Week Study of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

    open to eligible males ages 12-17

    This is a 52-week open label single arm study to investigate the effects of XYOSTED, as testosterone replacement therapy, on adolescent males with either primary or secondary hypogonadism. The study aims to determine the effectiveness of XYOSTED measured by continuation or induction of puberty in addition to XYOSTED dosage, safety and testosterone levels.

    at UCSF

  • EndoPAT Device for Endothelial Dysfunction in ED

    open to eligible males ages 18 years and up

    To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound. To evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy. To investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testosterone (T) therapy

    at UC Irvine

Our lead scientists for Hypogonadism, Male research studies include .

Last updated: